Marlio Charles Mosseri

10% owner · Nuvectis Pharma

Marlio Charles Mosseri (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Nuvectis Pharma, Inc. (NVCT). Across 1 priced purchase filing, the average 21-session return was -0.7% from execution and +22.3% from disclosure (delay-adjusted; derived). The largest single filing was $916K of NVCT (50,000 sh × $18.32, as filed), executed Jun 30. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-0.7%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+22.3%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$916K

shares × price, as filed

Last traded

Jun 30

Filed Jul 1

Median ADV $5.8M across their filed names

Impact on $10,000 · 12M

$12,210 (+22.1%)

S&P 500 $10,907 (+9.1%) · 13.0 pts ahead

Marlio Charles Mosseri S&P 500

Derived: compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $3.6M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

NVCT Nuvectis Pharma, Inc. NVCT · 6 buys · 0 sells 6 filings

Recent filings

NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $916K
50,000 sh × $18.32
Exec Jun 30
Filed Jul 1 · 1:41 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $957K
154,770 sh across 3 lots
Exec Oct 23 2025
Filed Oct 29 2025 · 8:00 AM ET † NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $226K
28,043 sh × $8.05
Exec Jun 18 2025
Filed Jun 20 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $172K
21,167 sh × $8.11
Exec May 12 2025
Filed May 13 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $1.2M
240,000 sh × $5.00
Exec Feb 7 2025
Filed Feb 11 2025 · 5:30 PM ET NVCTPURCHASE Nuvectis Pharma, Inc. View filing → $149K
32,121 sh × $4.64
Exec Dec 12 2024
Filed Dec 16 2024 · 5:30 PM ET